ArticleMedicine2020
Household financial burden among multidrug-resistant tuberculosis patients in Guizhou province, China: A cross-sectional study.
Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.Scientific reports · 2023Pooled it
- A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients.Scientific reports · 2022Pooled it
- Prevalence of Sleep Problems Among Chinese Medical Students: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2022Pooled it
- Factors associated with lost to follow-up (LTFU) among patients with hypertension: A scoping review.PLOS global public health · 2026Article
- Households of tuberculosis (TB) patients face high TB-related costs in Somalia.BMC global and public health · 2025Article
- The catastrophic cost of TB care: Understanding costs incurred by individuals undergoing TB care in low-, middle-, and high-income settings - A systematic review.PLOS global public health · 2025Article
- Latent Profile Analysis and Influencing Factors of Medication-Related Burden in Multidrug-Resistant Tuberculosis Patients in Chengdu, China.Patient preference and adherence · 2025Article
- Impact of financial support on treatment outcomes of multidrug-resistant tuberculosis: A population-based, retrospective cohort study in Shanghai, China.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Predicting hospitalization costs for pulmonary tuberculosis patients based on machine learning.BMC infectious diseases · 2024Article
- Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019.BMC infectious diseases · 2024Article
- South African adolescents' lived experiences of acquired hearing loss following multidrug-resistant tuberculosis treatment.Frontiers in rehabilitation sciences · 2024Article
- Active Surveillance of Antimicrobial Resistance and Carbapenemase-Encoding Genes According to Sites of Care and Age Groups in Mexico: Results from the INVIFAR Network.Pathogens (Basel, Switzerland) · 2023Article
- The Association Between Household Financial Burden and Patient Mobility and Their Impact on Loss to Follow-Up Among Multidrug-Resistant Tuberculosis Patients in Guizhou, China.Risk management and healthcare policy · 2023Article
- Article
- Direct Medical Expenses and Influencing Factors of MDR/RR-TB in Eastern China: Based on Data from Multi-Hospital Information Systems.Risk management and healthcare policy · 2023Article
- Health Risk, Income Effect, and the Stability of Farmers' Poverty Alleviation in Deep Poverty Areas: A Case Study of S-County in Qinba Mountain Area.International journal of environmental research and public health · 2022Article
- Spatial epidemiological characteristics and exponential smoothing model application of tuberculosis in Qinghai Plateau, China.Epidemiology and infection · 2022Article
- Factors associated with treatment outcomes of patients with drug-resistant tuberculosis in China: A retrospective study using competing risk model.Frontiers in public health · 2022Article
- Impacts of a comprehensive tuberculosis control model on the quality of clinical services and the financial burden of treatment for patients with drug-resistant tuberculosis in China: a mixed-methods evaluation.Infectious diseases of poverty · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Multidrug-resistant tuberculosis (MDR-TB) threatens global public health. Poor access to health care due to financial hardship contributes to further transmission of the disease. The study aimed to:A cross-sectional study was conducted in 2 hospitals designated for MDR-TB from January to August 2018. Data were collected by interviewing eligible MDR-TB outpatients and reviewing the medical records. The magnitude of financial burden was documented by total cost and distribution of cost components. Catastrophic payments were measured by 2 indicators: catastrophic health expenditure (CHE) and catastrophic total costs (CTC), both of which were estimated by incidence and intensity. Their associated factors were determined using logistic regression models.Of 161 households affected by MDR-TB, the average total costs due to MDR-TB treatment in the first year was US$ 8266 and consisted of 72% direct medical costs, 5% direct non-medical costs and 23% indirect costs (income loss). Thirty seven percent of direct medical costs were covered by insurance. Overall, the incidence of CHE and CTC was 68.3% and 87.0%, respectively. Both incidence and intensity for the 2 defined catastrophic costs increased when a households income decreased. Five significant factors of catastrophic costs were low household income, absence of students in a family, hospital length of stay, male gender, and job/productivity loss.Households with MDR-TB patients shouldered a high financial burden which was mainly driven by direct medical costs and income loss in Guizhou. Greater catastrophic payments were associated with hospital length of stay and socioeconomic status, especially had a dose-response relationship with households income. Our findings suggest that financial and social protection of local policies for MDR-TB should be improved by preparing a uniform and comprehensive insurance package to cover sufficiently direct medical costs, and introducing social pro-poor assistance policies for risk families to protect them from financial hardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.